MLH3

Across TCGA pan-cancer cohorts, MLH3 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated MLH3 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher MLH3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MLH3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

THYM, SCLC, and BRCA are the cancer types where MLH3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
SCLC	DFS	Median	All	0.175	0.651	<.001	24	view →
BRCA	OS	Median	III,IV	0.198	0.833	<.001	20	view →
UCEC	DFS	Median	All	0.927	0.614	.010	20	view →
HNSC	DFS	Median	III,IV	0.087	0.680	<.001	12	view →
LIHC	DFS	Median	All	0.147	0.558	.002	9	view →
TGCT	DFS	Median	All	0.172	0.801	.033	6	view →
GBM	DFS	Median	All	1.000	0.204	.042	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.258	0.787	.018	6	view →
COAD	OS	Median	III,IV	0.168	0.692	.043	3	view →
SKCM	DFS	Median	All	1.000	0.729	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

MLH3–THYM (OS)

Open the THYM breakdown →